Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversity Hospital Tuebingen
About this trial
The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.
Eligibility criteria
Qualifiers
BMI between 18.5 and 24.9 kg/m2; and between 27.5 kg/m2 and 40 kg/m2
Written consent to participate in the study
Written consent to be informed about incidental findings
Disqualifiers
Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke
BMI < 18.5 or > 40 kg/m2
Persons who cannot legally give consent
Pregnancy or lactation
Trial design
Treatments tested in this trial
- Subcutaneous GLP1-RA
- Subcutaneous placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1University Clinic Tubingen, Department of Internal Medicine IV72076, Tübingen Germany
Sponsors and collaborators
University Hospital Tuebingen
Lead sponsor
Source ClinicalTrials.gov